Table 3.
Serum analytes significantly elevated in COPD among older current smokers
| Analytea | T54 COPD/Ctr1b | BioServe COPD/Ctr1 | T54 COPD/Ctr2 | BioServe COPD/Ctr2 | ||||
|---|---|---|---|---|---|---|---|---|
| Fold/controlc | FDRc | Fold/control | FDR | Fold/control | FDR | Fold/control | FDR | |
| COPD > Control | ||||||||
| CD40 Ligand | 102.5 | < 10-8 | 282.0 | < 10-8 | 102.5 | < 10-8 | 282.0 | < 10-8 |
| EGF | 16.3 | < 10-8 | 48.3 | < 10-8 | 71.5 | < 10-8 | 211.5 | < 10-8 |
| BDNF | 54.0 | < 10-8 | 63.9 | < 10-8 | 58.5 | < 10-8 | 69.3 | < 10-8 |
| RANTES | 12.0 | < 10-8 | 16.9 | < 10-8 | 14.1 | < 10-8 | 19.8 | < 10-8 |
| Myeloperoxidase | 6.8 | < 10-8 | 24.2 | < 10-8 | 6.5 | < 10-8 | 23.1 | < 10-8 |
| Eotaxin | 8.9 | < 10-8 | 10.8 | < 10-8 | 8.9 | < 10-8 | 10.8 | < 10-8 |
| EN-RAGE | 3.1 | < 10-8 | 25.5 | < 10-8 | 2.3 | 1.5 × 10-5 | 19.4 | < 10-8 |
| Ferritin | 5.6 | < 10-8 | 8.7 | < 10-8 | 2.9 | < 10-8 | 4.5 | < 10-8 |
| IL-1RA | 5.6 | < 10-8 | 28.4 | < 10-8 | 3.5 | < 10-8 | 17.6 | < 10-8 |
| ENA-78 | 5.9 | < 10-8 | 8.1 | < 10-8 | 7.8 | < 10-8 | 10.8 | < 10-8 |
| PAI-1 | 7.5 | < 10-8 | 8.1 | < 10-8 | 5.3 | < 10-8 | 5.7 | < 10-8 |
| MCP-1 | 2.8 | < 10-8 | 2.8 | < 10-8 | 4.5 | < 10-8 | 4.5 | < 10-8 |
| MIP-1beta | 2.5 | < 10-8 | 3.4 | < 10-8 | 2.6 | < 10-8 | 3.5 | < 10-8 |
| Thrombopoietin | 2.9 | < 10-8 | 3.1 | < 10-8 | 2.9 | < 10-8 | 3.1 | < 10-8 |
| TIMP-1 | 2.7 | < 10-8 | 3.0 | < 10-8 | 3.1 | < 10-8 | 3.3 | < 10-8 |
| IL-16 | 1.8 | < 10-8 | 5.7 | < 10-8 | 1.7 | < 10-8 | 5.4 | < 10-8 |
| VEGF | 2.1 | < 10-8 | 2.9 | < 10-8 | 2.6 | < 10-8 | 3.6 | < 10-8 |
| Cancer antigen 19-9 | 2.0 | 0.0026 | 2.2 | 0.0084 | 1.6 | 0.18 | 1.8 | 0.25 |
| CD40 | 1.7 | < 10-8 | 3.1 | < 10-8 | 1.7 | < 10-8 | 3.2 | < 10-8 |
| Creatine kinase-MB | 2.1 | 0.0023 | 2.3 | 0.0006 | 2.1 | 0.044 | 2.3 | 0.0063 |
| C-reactive protein | 1.7 | 0.019 | 2.0 | 0.0076 | 1.7 | 0.077 | 2.0 | 0.036 |
| Myoglobin | 2.1 | 9.2 × 10-6 | 1.8 | 0.0011 | 1.4 | 0.0023 | 1.2 | 0.074 |
| Stem cell factor | 1.7 | < 10-8 | 1.8 | < 10-8 | 1.9 | < 10-8 | 2.1 | < 10-8 |
| IL-18 | 1.7 | < 10-8 | 2.4 | < 10-8 | 1.4 | 4.5 × 10-6 | 2.0 | < 10-8 |
| TNF-RII | 1.4 | < 10-8 | 1.7 | < 10-8 | 1.5 | < 10-8 | 1.8 | < 10-8 |
| COPD < Control | ||||||||
| IGF-1 | -6.0 | 0.00018 | -3.8 | 6.5 × 10-6 | -6.6 | 8.6 × 10-6 | -4.2 | < 10-8 |
| IgE | -4.1 | 0.025 | -3.2 | 0.019 | -3.4 | 0.0050 | -2.6 | 0.0068 |
aBaseline levels of analytes reported in Table 2 to be associated with COPD vs control, restricted to current smokers between the ages of 50 and 70, inclusive.
bThe subpopulation sizes were: T54, n = 104; BioServe, n = 50; Ctr1, n = 33; Ctr2, n = 19.
cFDR and signed-fold levels in COPD over controls (fold/control) are provided for each subpopulation. FDR > 0.05 are shown in bold.
BDNF, brain-derived neurotrophic factor; COPD, chronic obstructive pulmonary disease; EGF, epidermal growth factor; ENA, epithelial-derived neutrophil activating protein; EN-RAGE, extracellular newly identified-receptor for advanced glycation end-binding protein; FDR, false discovery rate; IgE, immunoglobulin E; IGF, insulin-like growth factor; IL, interleukin; -MB, -muscle/brain; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; PAI, plasminogen activating factor; RA, receptor agonist; RANTES, regulated upon activation, normally T-cell expressed, and secreted; TIMP, tissue inhibitor of metalloproteinases; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.